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Background: The use of growth factor agents in the regen-
eration of oral tissues is an area of current investigation. Com-
binations of growth factors have been used synergistically to
improve tissue regeneration. The aim of this study was to deter-
mine the effects of a combination growth factor cement (GFC)
on guided bone regeneration around dental implants.
Methods: A combination of bone morphogenetic protein-2
(BMP-2), transforming growth factor-β (TGF-β), platelet-derived
growth factor (PDGF), and basic fibroblast growth factor (bFGF)
was used in a bioabsorbable, non-hydroxyapatite, calcium phos-
phate cement. Five adult hound dogs were used to compare the
effects of GFC, plain cement, and control (no cement). The right
and left second, third, and fourth mandibular premolar teeth were
extracted; the implant osteotomies were prepared; and a uniform
circumferential gap was prepared 1.5 mm beyond the width of
the implant in the coronal half of the osteotomy for cement place-
ment. Titanium machine-polished dental implants were placed
in the prepared sites, and coronal defects were treated accord-
ing to previously randomized, assigned modality. A bioabsorbable
collagen membrane was secured over the control site, and the
flaps were closed primarily. The dogs were maintained on a soft
diet to avoid soft tissue trauma. The dogs were sacrificed at 3
months. The specimens were sectioned, mounted, and stained
with Stevenel’s blue and van Gieson’s picric fuchsin. The bone-
to-implant contact and bone 1 mm peripheral to the implant sur-
face were recorded with a computerized microscopic digitizer.
Results: The findings of this study indicate a significant effect
of GFC on increased bone-to-implant contact and amount of
bone per surface area compared with the other treatment modal-
ities (P <0.0009). Plain cement demonstrated slight but non-
significant increases compared with the control (P >0.05).
Conclusions: GFC increases bone-to-implant contact and
bone surface area within peri-implant defects. Further studies
may be beneficial to determine the feasibility of its use for other
regenerative applications. J Periodontol 2000;71:8-13.
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T
he improved success of dental
implants has been an ongoing area
of research. Improvement in dental
implant wound healing is a current area of
investigation, and use of biologic mediators
to improve the quantity and quality of the
supporting bone has shown promise.1-6 Of
particular interest are the polypeptide
growth and differentiation factors, which
have been shown to help in the regulation
and stimulation of the healing process.
Growth factors have been found in healing
wound tissues, bone, and cementum,7 and
have been shown to enhance cell prolifer-
ation, differentiation, chemotaxis, and extra-
cellular matrix synthesis.8-16
The use of several growth factors in peri-
implant bone healing has yielded improve-
ments in bone-implant contact as well as
rate of bone regeneration.2-6 The use of
bovine bone morphogenetic protein (bBMP)
in the preclinical model has been shown to
increase the rate of formation of peri-
implant bone, in addition to bone-implant
contact in early healing.5,6 Osteogenic pro-
tein (OP-1), platelet-derived growth factor
(PDGF), and insulin-like growth factor-I
(IGF-I) have also been shown to be influ-
ential in improving the regeneration of peri-
implant bone.2-4
Although the role and use of individual
growth factors remain an area of study, the
use of combinations of growth factors has
shown synergistic improvements in heal-
ing.17-20 The use of a PDGF and IGF com-
bination, as well as a PDGF and trans-
forming growth factor-alpha (TGF-α) com-
bination, has resulted in synergistic effects
in vivo.18,19 The use of growth factor com-
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binations to improve the healing response might fur-
ther assist in the complex cellular events and interac-
tions that normally occur during healing.
Several growth and differentiation factors have been
identified during embryologic development of alveolar
bone.21-23 Recently, a combination of BMP-2, TGF-β,
basic fibroblast growth factor (bFGF), and PDGF has
been isolated from embryologic tissues and shown to
improve the mitogenic response of dermal fibroblasts
and osteoblastic cells in vitro (unpublished observa-
tions). The combination was roughly 2 parts of TGF-
β and bFGF by weight to 1 part BMP-2 and PDGF. A
similar 21 ratio was reported as optimal in the use of
a PDGF-2 and IGF-I combination.18
The aim of this study was to examine the effects of
a combination growth factor cement (GFC) on guided
bone regeneration in the repair of peri-implant osseous
defects. This model was chosen for the bioabsorbable
cement to act as a carrier device for the sustained
delivery of growth factors during osseous healing of
peri-implant defects. The combination included BMP-
2, TGF-β, bFGF, and PDGF, each of which has been
shown to influence the healing response.24-39
MATERIALS AND METHODS
The GFC included (in pg/mg of cement) approximately
1.2 pg TGF-β, 1.2 pg bFGF, 0.5 pg BMP-2, and 0.6
pg PDGF, or roughly a 21 combination of TGF-β and
bFGF to BMP-2 and PDGF, respectively. These factors
were obtained through purification of developing
porcine oral tissues. In each defect, approximately 60
mg of cement was used. Previous in vitro testing ver-
ified the biologic activity of the growth factors to stim-
ulate the proliferation of osteoblasts to numbers 50%
over control cell numbers after 4 days in culture, and
the ability of the cement to set, which had a working
time of approximately 7 minutes.
Five adult male hound dogs were used because the
jaw size was adequate for endosteal implant place-
ment. This study was approved by the Institutional
Animal Care and Use Committee of Mayo Foundation.
Thirty titanium machine-polished implants¶ were used
and distributed evenly among 3 treatment groups:
GFC, plain cement, and control. There were 3 implants
per mandible side, with 10 implants per treatment vari-
able.
Each dog was given 4% thiamylan sodium (20
mg/kg) intravenously.# The animals were intubated
after induction of general anesthesia and maintained
with 1% halothane inhalational anesthetic together with
a 50% mixture of nitrous oxide and oxygen. The sur-
gical sites were disinfected with a sterile swab of povi-
done-iodine and anesthetized locally with 2% lidocaine
HCl with 1100,000 epinephrine for improved hemo-
stasis and postoperative analgesia. Full-thickness
mucoperiosteal flaps were incised and reflected on the
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 Bone-derived ADMAT, Tissue Engineering, Inc., Boston, MA.
¶   Brånemark, Nobel Biocare, Westmont, IL.
#   Surital, Parke-Davis Co., Detroit, MI.
** Biomend, Calcitek, Carlsbad, CA.
†† IMTEC, Ardmore, OK.
‡‡ Torbugesic, Aveco Co. Inc., Fort Dodge, IA.
§§ Flo-Cillin, Fort Dodge Laboratories, Inc., Fort Dodge, IA.
 Science Diet, Hill’s Pet Nutrition, Inc., Topeka, KS.
facial and lingual aspects of the teeth to be extracted.
The second, third, and fourth mandibular premolar
teeth were extracted bilaterally as atraumatically as
possible by midcoronal facial-to-lingual sectioning with
a high-speed handpiece with a sterile water-cooled bur
and standard dental forceps. After odontectomy, alve-
oloplasty was performed on the remaining alveolar
ridge for improved form and elimination of bony
spicules before implant placement. Next, standard
implant osteotomy preparations were performed with
sterile water cooling in the residual alveolus area. The
coronal half of the implant preparation was widened to
5.25 mm with a trephine bur.
Three endosteal dental implants of 3.75 mm width
and 8 mm length were surgically placed in each side
of the mandible (Fig. 1), according to previously ran-
domized, assigned modality. Cover screws were placed
to cover the implants. A bioabsorbable collagen mem-
brane** was placed over the “no cement” control sites
to allow a space for bony ingrowth and prevent soft tis-
sue ingrowth,40 since the cement in the other groups
acted as a barrier for soft tissue ingrowth, serving this
purpose. The cement groups did not receive a mem-
brane because the hardened cement acted as its own
barrier. The membranes were secured in place with
bone tacks†† to prevent movement of the membrane.
The cement treatments were prepared and packed into
the 0.75 mm circumferential defects according to pre-
viously randomized, assigned modality. Surgical flaps
were reapproximated and closed primarily with 4-0
polyglactin 910 sutures.
Postoperatively, butorphanol‡‡ (0.2 to 0.4 mg/kg
every 2 to 5 hours) was administered intramuscularly
as needed for discomfort, and a 300,000 IU/ml prepa-
ration of penicillin G benzathine and penicillin G pro-
caine§§ (1 ml/5 to 10 kg) was given intramuscularly
to reduce the potential for infection. The dogs were
kept in the recovery room until they overcame the
effects of general anesthesia and their condition was
stable. For the rest of the study, they were fed a soft
diet  to reduce potential trauma to the surgical sites.
Histologic examination occurred after a 3-month
healing period. This period was chosen to evaluate
any differences after a standard healing period.41 The
dogs were euthanized as scheduled with an overdose
of sodium pentobarbital, and mandible specimens col-
lected with the use of a band saw. Following collec-
tion, specimens were fixed, sectioned, and mounted
as previously described.1 All specimens were then
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coded prior to analysis so that the examiner was
unaware of the treatment group, to allow for a blinded
examination.
Histologic specimens were examined with trans-
mitted light at a magnification of ×100. The implant and
peri-implant tissues, including bone-implant contact and
amount of bone per area, were analyzed with the use
of a semi-automated computerized technique,¶¶ in which
a microscope was interfaced with a computer and dig-
itizer. The bone-implant contact was traced with the
digitizer and recorded as a value, which was converted
to a percentage of bone in contact
with the implant surface. The amount
of bone per area in each field (0.507
mm2) was traced with the digitizer
and recorded as an area value, 2
fields from the implant surface, along
the length of the implant. This value
was then converted to a mean per-
centage of the total area per field.
Statistical Analysis
The primary response variables were
the percentage of the length of the
implant section in contact with bone
and the percentage of bone per area,
as measured by histologic examina-
tion. Treatment effects were evalu-
ated using an analysis of variance
(ANOVA) mixed model with terms
for animal, position, side, and treat-
ment, with animal handled as a ran-
dom effect. Least-squares means
were estimated to account for the
imbalance in the study design result-
ing from 4 measurements not being
available (all 3 treatments on the
right side of one animal and one
treatment on the right side of another
animal). Pairwise differences of the
least-squares means using the cor-
responding standard errors were as-
sessed with t tests. All P values were 2-sided, and a
type I error level of 0.05 was used.
RESULTS
The results for the histomorphometric data are sum-
marized in Tables 1 and 2. The primary response vari-
ables were percentage of bone-implant contact and
percentage of peripheral bone per area, as measured
histologically.
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Figure 1.





Treatment Mean SD Minimum Maximum
GFC 77.4 7.2 67.5 87.8
PC 59.7 12.6 32.1 75.6
Control 54.8 12.3 27.9 67.6
GFC, growth factor cement; PC, plain cement.
Table 2.
Bone Per Area
Bone Per Area (%)
Treatment Mean SD Minimum Maximum
GFC 76.8 3.7 70.9 81.0
PC 67.4 6.2 57.4 76.5 
Control 64.0 4.2 57.3 68.2
GFC, growth factor cement; PC, plain cement.
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Of the 30 implants, 3 were lost in a dog that had
an abnormal chewing habit on one side of the
mandible; there was one implant in each treatment
group. One additional implant in the control group was
lost as a result of processing error. There were 9
implants per group in the GFC and plain cement
groups and 8 implants in the con-
trol group for comparisons. No
exposures were encountered with
the remaining implants.
For mean percentage of bone-
to-implant contact, GFC demon-
strated a 17.7% (P = 0.0008) and
22.6% (P <0.0001) improvement
over plain cement and the con-
trol, respectively (Table 1). The
plain cement demonstrated a
mean improvement of 4.9% over
the control; however, this differ-
ence was not significant (P =
0.12).
For mean percentage of periph-
eral bone per area, GFC had the
greatest effect (Table 2). An
improvement of 9.4% was demon-
strated over plain cement (P =
0.0009) and 12.8% over the con-
trol (P <0.0001). A difference of
3.4% was seen between plain
cement and control, but this was
not significant (P = 0.12).
DISCUSSION
The present study examined the effects of a combi-
nation growth factor cement on bone regeneration in
peri-implant defects. Evaluation of the effects involved
histometric analysis of the bone-implant contact and
peripheral implant supporting bone, up to 1 mm from
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Figure 2.
Residual cement particles (Stevenel’s blue and van Gieson’s picric fuchsin stain; ×200).
Figure 3.
Coronal portion of the implant. Osseous overgrowth on the left GFC specimen, and normal osseous level on the right control specimen (Stevenel’s blue
and van Gieson’s picric fuchsin stain; ×20).
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the threaded surface, after a 3-month healing period.
The bioabsorbable non-hydroxyapatite calcium phos-
phate cement was completely replaced by bone along
the implant surfaces. However, in a few slides, some
residual cement particles were present superior to the
implants. The particles were incorporated within bone,
without evidence of soft tissue encapsulation, and not
surrounded by inflammatory cells (Fig. 2). Therefore,
the cement was well tolerated.
The use of GFC resulted in an improvement of both
the bone-implant contact and the amount of periph-
eral bone per area. Because this is the first test of this
growth factor combination with this vehicle, we are
unable to make direct comparisons to previous stud-
ies. However, other combinations have been studied
with peri-implant bone healing. Becker et al.3 found a
17.9% improvement in bone-implant contact after 18
weeks of healing with a PDGF/IGF-I combination com-
pared to ePTFE membrane alone. Lynch et al.4 found
an 8.7% increase in bone-implant contact in early heal-
ing with a PDGF-B/IGF-I combination. The difference
between test and control groups eventually became
much smaller and non-significant in later healing. In
terms of peripheral peri-implant bone, Becker et al.
found a 26.5% improvement after 18 weeks, while
Lynch et al. found a 26.8% improvement in the test
group compared with the control at 3 weeks of heal-
ing.3,4 This difference is larger than the 12.8% improve-
ment of our GFC over the control, which can be attrib-
uted to increased amounts of bone in our control group.
Of particular interest is the combination dosage used
in this study; it was much smaller than the dosages of
5 µg and 4 µg for the Becker et al. and Lynch et al.
studies, respectively.
The use of polypeptide growth and differentiation
factors has been shown to improve implant-support-
ing bone. Combinations of growth factors might be of
extended benefit over single growth factor use in early
bone healing, which may address the complexity of
the required cellular events and interactions that nor-
mally occur in the healing process. The particular com-
bination used in this study actually induced bone
growth beyond the cover screw of a few test implants
(Fig. 3). This goes beyond the biologic activity usu-
ally seen in implant healing, in which the crestal bone
height is usually maximally at the level of polished
collar or first thread.42 Further studies would be help-
ful to explore other applications of GFC, in addition to
improvements of implant-supporting bone.
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